246 related articles for article (PubMed ID: 25862024)
1. Topical corticosteroid-induced skin atrophy: a comprehensive review.
Barnes L; Kaya G; Rollason V
Drug Saf; 2015 May; 38(5):493-509. PubMed ID: 25862024
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial.
Cossmann M; Welzel J
Br J Dermatol; 2006 Oct; 155(4):700-6. PubMed ID: 16965418
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of anti-inflammatory and atrophogenic effects of glucocorticoids on reconstructed human skin.
Weindl G; Castello F; Schäfer-Korting M
Altern Lab Anim; 2011 May; 39(2):173-87. PubMed ID: 21639680
[TBL] [Abstract][Full Text] [Related]
4. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy.
McMichael AJ; Griffiths CE; Talwar HS; Finkel LJ; Rafal ES; Hamilton TA; Voorhees JJ
Br J Dermatol; 1996 Jul; 135(1):60-4. PubMed ID: 8776360
[TBL] [Abstract][Full Text] [Related]
5. Eczematous Drug Eruptions.
Blum AE; Burgin S
Am J Clin Dermatol; 2021 May; 22(3):349-366. PubMed ID: 33587283
[TBL] [Abstract][Full Text] [Related]
6. Anti-proliferative and anti-inflammatory effects of 3β,6β,16β-Trihydroxylup-20(29)-ene on cutaneous inflammation.
Horinouchi CD; Mendes DA; Nolte S; Brito PS; Soley BD; Favero GM; Facundo VA; Santos AR; Cabrini DA; Otuki MF
J Ethnopharmacol; 2017 Jan; 195():298-308. PubMed ID: 27880883
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the atrophogenic potential of topical corticosteroids in pediatric dermatology patients.
Hong E; Smith S; Fischer G
Pediatr Dermatol; 2011; 28(4):393-6. PubMed ID: 21507057
[TBL] [Abstract][Full Text] [Related]
8. A study to assess the occlusivity and moisturization potential of three topical corticosteroid products using the skin trauma after razor shaving (STARS) bioassay.
Kircik LH
J Drugs Dermatol; 2014 May; 13(5):582-5. PubMed ID: 24809882
[TBL] [Abstract][Full Text] [Related]
9. Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement.
Mooney E; Rademaker M; Dailey R; Daniel BS; Drummond C; Fischer G; Foster R; Grills C; Halbert A; Hill S; King E; Leins E; Morgan V; Phillips RJ; Relic J; Rodrigues M; Scardamaglia L; Smith S; Su J; Wargon O; Orchard D
Australas J Dermatol; 2015 Nov; 56(4):241-51. PubMed ID: 25752907
[TBL] [Abstract][Full Text] [Related]
10. [Development and regression of dermal corticosteroid atrophy. 3. Results of discontinuous topical corticosteroid administration].
Bensmann A; Lubach D
Derm Beruf Umwelt; 1987; 35(1):20-3. PubMed ID: 2952481
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography.
Aschoff R; Schmitt J; Knuschke P; Koch E; Bräutigam M; Meurer M
Exp Dermatol; 2011 Oct; 20(10):832-6. PubMed ID: 21771098
[TBL] [Abstract][Full Text] [Related]
12. Dorsal skin reactions of hairless dogs to topical treatment with corticosteroids.
Kimura T; Doi K
Toxicol Pathol; 1999; 27(5):528-35. PubMed ID: 10528632
[TBL] [Abstract][Full Text] [Related]
13. Contact dermatitis: relevant differential diagnoses, simulators, and variants.
Kränke B; Schuster C
J Dtsch Dermatol Ges; 2015 Nov; 13(11):1073-88; quiz 1089. PubMed ID: 26513065
[TBL] [Abstract][Full Text] [Related]
14. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm.
Luger T; De Raeve L; Gelmetti C; Kakourou T; Katsarou A; Lambert J; Morren MA; Oranje A; Ruer M; Serdaroglu S; Torrelo A; Werfel T
Eur J Dermatol; 2013; 23(6):758-66. PubMed ID: 24185493
[TBL] [Abstract][Full Text] [Related]
15. [Development and regression of dermal corticosteroid atrophy. 1. Change in the skinfold thickness].
Lubach D; Hinz E
Derm Beruf Umwelt; 1986; 34(5):146-9. PubMed ID: 2947794
[TBL] [Abstract][Full Text] [Related]
16. Real-world safety evaluation of topical corticosteroid use: A community pharmacy-based, prospective, observational study.
Ah YM; Hwang S; Jun K; Choi SA; Yu YM; Kim E; Kim DY; Shin WG; Lee JY
Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):405-413. PubMed ID: 30983117
[TBL] [Abstract][Full Text] [Related]
17. [Contact allergy for corticosteroids].
de Groot AC; van Ginkel CJ; Bruynzeel DP
Ned Tijdschr Geneeskd; 1997 Aug; 141(32):1559-62. PubMed ID: 9543750
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel in vitro test systems for the determination of glucocorticoid receptor ligand-induced skin atrophy.
Schoepe S; Schäcke H; Bernd A; Zöller N; Asadullah K
Skin Pharmacol Physiol; 2010; 23(3):139-51. PubMed ID: 20051715
[TBL] [Abstract][Full Text] [Related]
19. Multiple corticosteroid orally elicited allergic contact dermatitis in a patient with multiple topical corticosteroid allergic contact dermatitis.
Chew AL; Maibach HI
Cutis; 2000 May; 65(5):307-11. PubMed ID: 10826093
[TBL] [Abstract][Full Text] [Related]
20. Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy.
Werfel T
J Dtsch Dermatol Ges; 2009 Sep; 7(9):739-42. PubMed ID: 19650820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
